CRISPR Therapeutics AG (FRA:1CG)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.31B -0.5% |
| Revenue (ttm) | 22.17M -34.3% |
| Net Income | -401.67M |
| EPS | -4.25 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 44.56 |
| Previous Close | 44.80 |
| Day's Range | 44.56 - 44.56 |
| 52-Week Range | 37.60 - 55.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Feb 11, 2027 |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve... [Read more]
Financial Performance
In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.
Financial numbers in USD Financial StatementsNews
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will participate in a fireside chat at the ...
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) ...
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders...
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from ...
Crispr Therapeutics price target lowered to $80 from $81 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $81 and keeps a Buy rating on the shares.
Crispr Therapeutics price target raised to $90 from $88 at Citi
Citi raised the firm’s price target on Crispr Therapeutics (CRSP) to $90 from $88 and keeps a Buy rating on the shares post the Q3 report. The firm says the…
Crispr Therapeutics price target lowered to $70 from $75 at Wells Fargo
Wells Fargo lowered the firm’s price target on Crispr Therapeutics (CRSP) to $70 from $75 and keeps an Equal Weight rating on the shares. The firm notes CASGEVY revenue grew…
Crispr Therapeutics reports Q3 EPS ($1.15), consensus ($1.00)
Reports Q3 revenue $12.669M, consensus $16.56M. “The third quarter marked meaningful progress for CRISPR Therapeutics (CRSP),” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRI...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age ...
CRISPR Therapeutics AG Earnings release: Q3 2026
CRISPR Therapeutics AG released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
CRISPR Therapeutics AG Quarterly report: Q3 2026
CRISPR Therapeutics AG has published its Q3 2026 quarterly earnings report on November 2, 2026.
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, ef...
Crispr Therapeutics CFO Raju Prasad to step down, A.J. Silver to succeed
Crispr Therapeutics (CRSP) announced that its CFO, Raju Prasad will be stepping down from the company to pursue external opportunities, and A.J. Silver, the company’s senior VP of finance, will…
CRISPR Therapeutics Announces Chief Financial Officer Transition
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the C...
Crispr Therapeutics initiated with a Neutral at UBS
UBS initiated coverage of Crispr Therapeutics (CRSP) with a Neutral rating and $52 price target The company’s validated genome editing platform is a historic first with an approved cell therapy,…
Crispr Therapeutics price target lowered to $81 from $82 at BofA
BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $81 from $82 and keeps a Buy rating on the shares as part of a Q3 earnings preview for…
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9...
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its in...
CRISPR Therapeutics AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
CASGEVY’s pediatric label expansion and strong payer coverage are driving rapid revenue growth, while three key assets—CTX310, zugo-cel, and CTX611—are advancing toward pivotal trials. The pipeline is supported by robust research, AI-driven productivity, and a focus on global expansion and next-generation gene editing.
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th An...
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
After Crispr Therapeutics (CRSP) presented durability data from its Phase 1 trial of CTX310 gene editing therapy targeting ANGPTL3, Morgan Stanley called the data “encouraging,” but adds that the firm...
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reduction...
CRISPR Therapeutics AG Slides: Corporate presentation
CRISPR Therapeutics AG has posted slides in relation to its latest quarterly earnings report, which was published on August 28, 2026.
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Crispr Therapeutics (CRSP) to $55 from $48 and keeps a Neutral rating on the shares.
Crispr Therapeutics price target lowered to $82 from $83 at BofA
BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $83 and keeps a Buy rating on the shares. The firm adjusted targets for several companies in…